The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Freezing of Gait, 2024Adaptive Cortical Neuromodulation Using a Brain-machine Interface to Treat Freezing of Gait in Parkinson’s Disease
Study Rationale: Difficulties with walking can have significant impacts on the quality of life of people with Parkinson’s (PwP). One of the most serious is freezing of gait (FOG), which are brief but...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of a First-in-class Inhibitor of the “Mitochondrial Permeability Transition Pore” as a Novel Disease-modifying Treatment for Parkinson’s Disease
Study Rationale: Mitochondria are subcellular structures that produce energy and help regulate the movement of calcium ions that continually flow into brain cells when they are active, ions that can...
-
Research Grant, 2024Measurement of Phosphorylated Alpha-synuclein in Skin Biopsies as a Prospective Biomarker for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is associated with an accumulation of phosphorylated alpha-synuclein, and the amount of the protein increases as PD progresses. We have found that we can...
-
Research Grant, 2024Developing Community Health Worker Remote Training Modules on Research, Brain Health and Parkinson’s Disease
Study Rationale: Neurodegenerative diseases including Parkinson's disease (PD) disproportionately impact underserved communities due to barriers in research participation and awareness. Community...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Novel LRRK2 Inhibitors for the Treatment of Parkinson’s Disease
Study Rationale: Inhibitors of the LRRK2 protein offer promise as a therapy for Parkinson’s disease (PD). The leading inhibitors currently under development, the so-called Type 1 kinase inhibitors...
-
Research Grant, 2024Assessment of Longitudinal Imaging Using Radiolabeled AV-133 in Early and Prodromal Parkinson’s Disease
Study Rationale: The clinical phase of Parkinson’s disease (PD) is preceded by a prodromal phase of progressing neurodegeneration that can last many years. Imaging markers such as radiolabeled AV-133...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.